Authors

Latest:

The Role of Genetic Profiling in Secondary AML

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.

Parissa Tabrizian, MD

Latest:

Dr. Tabrizian on the Rationale for Examining Cemiplimab in HCC

Parissa Tabrizian, MD, discusses the rationale for examining cemiplimab in hepatocellular carcinoma.

Rahul Gosain, MD

Latest:

How Generalists Are Uniquely Positioned to Administer and Advance Oncology Care: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

Yung Lyou, MD, PhD

Latest:

Dr. Lyou on Key Takeaways from the ENZAMET Trial in Metastatic Prostate Cancer

Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.

Miranda Lankas

Latest:

Ra-223 Displays Efficacy, Safety in mCRPC With Bone Metastases

Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.

Karyn A. Goodman, MD, MS

Latest:

Dr Goodman on the Addition of CRT to Adjuvant Chemo in Pancreatic Head Adenocarcinomas

Karyn A. Goodman, MD, MS, discusses the use of chemoradiation after adjuvant chemotherapy in resected adenocarcinomas of the pancreatic head.

Joseph P. McGuirk, DO

Latest:

Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and Bispecifics

Expert perspective on advancements in cancer immunotherapy, including CAR-T cells, allogeneic strategies, and the role of bispecific antibodies.

Carolina D. Schinke, MD

Latest:

Dr Schinke on the Safety Profile of Talquetamab in Relapsed/Refractory Myeloma

Carolina D. Schinke, MD, discusses the safety profile of talquetamab-tgvs in the phase 1/2 MonumenTAL-1 trial of patients with relapsed/refractory multiple myeloma.

Katianne M. Howard Sharp, PhD

Latest:

Dr. Howard Sharp on the Importance of Racial and Ethnic Diversity in Pediatric Clinical Trials

Katianne M. Howard Sharp, PhD, discusses the importance of racial and ethnic diversity in clinical trials for pediatric patients with cancer.

Bruce Robinson, MD

Latest:

Differentiated Thyroid Cancer: Unmet Needs and Future Directions

Experts highlight remaining unmet needs in the management of radioiodine-refractory differentiated thyroid cancer and share their hopes for the future.

Tulane Cancer Center

Latest:

Tulane Doctors Extend Their Reach in 2024

The Tulane Transplant Institute offers comprehensive disease management for patients with end-stage organ disease of the kidney, liver, and pancreas.

Olivier Elemento, PhD

Latest:

Dr. Elemento on Utilizing Circulating Tumor Cells to Assess Treatment Resistance in mCRPC

Olivier Elemento, PhD, discusses utilizing circulating tumor cells to assess treatment resistance in metastatic castration-resistant prostate cancer.

Maurice Perol, MD, Léon Bérard Cancer Center

Latest:

Considerations of Adjuvant Therapy in EGFR+ ES-NSCLC

Rosario Ligresti, MD

Latest:

Dr. Ligresti on the Need for Screening in Pancreatic Cancer

Rosario Ligresti, MD, discusses the need for screening in pancreatic cancer.

Monica L. Baskin, PhD

Latest:

Dr. Baskin on Mitigating Patient Concerns During the COVID-19 Pandemic in Prostate Cancer

Monica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.

Andrew P. Jallouk, BS, MD, PhD

Latest:

Dr Jallouk on Preventing Post-Transplant Relapse in R/R Hematologic Malignancies

Andrew P. Jallouk, BS, MD, PhD, discusses research assessing post-transplant relapse prevention strategies in patients with hematologic malignancies.

Adam DuVall, MD, MPH

Latest:

Dr Duvall on Unanswered Questions Regarding the Optimal Role for Blinatumomab in B-ALL

Adam DuVall, MD, MPH, discusses remaining questions regarding the optimal use of blinatumomab in frontline B-ALL.

Talha Munir, MBChB, PhD

Latest:

Zanubrutinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic Analysis

An economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.

Sangeetha Venugopal, MD, MS

Latest:

Other Notable Myelofibrosis Data From ASH 2024

Sangeetha Venugopal, MD, MS, discusses other notable myelofibrosis data from the 2024 ASH Annual Meeting.

Minesh Mehta, MD

Latest:

Dr Mehta on Radiation Oncology Innovations in Prostate Cancer

Minesh Mehta, MD, discusses recent advancements in radiation oncology approaches for patients with prostate cancer.